BioMarin

In News

BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline - PR Newswire

PR Newswire - Aug 18, 2026

BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment - CNBC

CNBC - Aug 19, 2026

BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca - Fierce Biotech

Fierce Biotech - Aug 18, 2026

Piper Sandler reiterates Overweight on BioMarin stock at $88 target - Investing.com

Investing.com - Aug 26, 2026

BioMarin spends up to $490m for Alesta’s bone disease candidate - Pharmaceutical Technology

Pharmaceutical Technology - Aug 19, 2026

Our Origin Story - BioMarin Pharmaceutical

BioMarin Pharmaceutical - Jun 17, 2026

Why BioMarin Pharmaceutical (BMRN) Stock Is Up Today - Yahoo Finance

Yahoo Finance - Aug 19, 2026

BioMarin (BMRN) Earnings History & Trends - 24/7 Wall St.

24/7 Wall St. - Aug 27, 2026

BioMarin (NASDAQ:BMRN) Stands Out as an Undervalued Stock with Solid Fundamentals - ChartMill

ChartMill - Aug 24, 2026

BioMarin acquires experimental drug for rare bone disorder in $275M deal - BioPharma Dive

BioPharma Dive - Aug 18, 2026

BioMarin looks to spur growth with potential $490M buyout of Dutch bone drug company - The Business Journals

The Business Journals - Aug 18, 2026

BioMarin Reports Second Quarter 2026 Financial and Operating Results - PR Newswire

PR Newswire - Aug 06, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment